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Abstract
Background: Accurate diagnosis in patients with suspected coronavirus disease 2019 (COVID-19) is essential to
guide treatment and limit spread of the virus. The combined nasal and throat swab is used widely, but its
diagnostic performance is uncertain.
Methods: In a prospective, multi-centre, cohort study conducted in secondary and tertiary care hospitals in
Scotland, we evaluated the combined nasal and throat swab with reverse transcriptase-polymerase chain reaction
(RT-PCR) for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in consecutive patients admitted to
hospital with suspected COVID-19. Diagnostic performance of the index and serial tests was evaluated for a primary
outcome of confirmed or probable COVID-19, and a secondary outcome of confirmed COVID-19 on serial testing.
The diagnosis was adjudicated by a panel, who recorded clinical, laboratory and radiological features blinded to the
test results.
Results: We enrolled 1368 consecutive patients (median age 68 [interquartile range, IQR 53–80] years, 47% women)
who underwent a total of 3822 tests (median 2 [IQR 1–3] tests per patient). The primary outcome occurred in 36%
(496/1368), of whom 65% (323/496) and 35% (173/496) had confirmed and probable COVID-19, respectively. The
index test was positive in 255/496 (51%) patients with the primary outcome, giving a sensitivity and specificity of
51.4% (95% confidence interval [CI] 48.8 to 54.1%) and 99.5% (95% CI 99.0 to 99.8%). Sensitivity increased in those
undergoing 2, 3 or 4 tests to 60.1% (95% CI 56.7 to 63.4%), 68.3% (95% CI 64.0 to 72.3%) and 77.6% (95% CI 72.7 to
81.9%), respectively. The sensitivity of the index test was 78.9% (95% CI 74.4 to 83.2%) for the secondary outcome of
confirmed COVID-19 on serial testing.
Conclusions: In patients admitted to hospital, a single combined nasal and throat swab with RT-PCR for SARS-CoV-
2 has excellent specificity, but limited diagnostic sensitivity for COVID-19. Diagnostic performance is significantly
improved by repeated testing.
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Background
Severe acute respiratory syndrome coronavirus-2 (SARS-
CoV-2) is a novel coronavirus, which is responsible for
the global pandemic of coronavirus disease 2019
(COVID-19) [1, 2]. Timely and accurate diagnostic test-
ing in patients with suspected COVID-19 is essential to
guide treatment and implement infection control mea-
sures to limit spread of the virus.
Reverse transcriptase-polymerase chain reaction (RT-
PCR) assays on material collected by swabbing the naso-
pharynx and oropharynx, herein referred to as the com-
bined nose and throat swab, are the most commonly
used diagnostic tests [3]. However, a number of reports
have indicated discordance between the results of testing
and clinical or radiological findings in patients with
symptoms of suspected COVID-19 and increasingly
clusters of asymptomatic carriers of SARS-CoV-2 are
recognised [4–8]. As such, uncertainty remains as to the
diagnostic performance of the combined nasal and
throat swab to diagnose the clinical condition of
COVID-19, particularly in patients presenting late fol-
lowing the onset of symptoms when the viral load may
be lower.
Our aim was to evaluate the performance of the com-
bined nasal and throat swab for the clinical diagnosis of
COVID-19 in consecutive patients admitted to hospital
with suggestive symptoms, and to determine whether
there is heterogeneity across subgroups.
Methods
Study design
In a prospective, multi-centre, cohort study in secondary
and tertiary care hospitals in Scotland, United Kingdom,
we evaluated the diagnostic performance of the com-
bined nasal and throat swab with RT-PCR for SARS-
CoV-2 in consecutive patients admitted to hospital for
symptoms of suspected COVID-19. The study was per-
formed with approval of the local Research Ethics Com-
mittee and delegated Caldicott Guardian for the
National Health Service (NHS) Lothian Health Board, in
accordance with the Declaration of Helsinki. All data
were collected from the patient record and national
registries, deidentified and linked in a data repository
(DataLoch, Edinburgh, United Kingdom) within a secure
safe haven. To ensure that every eligible patient was in-
cluded and avoid selection bias, consent was not sought
from individual patients. Only summary data was ex-
tracted to minimise the risk of disclosure.
Participants
Consecutive adult patients ≥18 years old were identified
by the attending clinician using an electronic form inte-
grated into the care pathway at the time of testing with
the combined nasal and throat swab. Patients were
eligible for inclusion if they were admitted to hospital
with symptoms suggestive of COVID-19 and had a re-
portable SARS-CoV-2 RT-PCR result from material ob-
tained through the combined swab (Fig. 1). Patients
were excluded if they had no symptoms and testing was
performed for screening purposes only, or if they had a
previous diagnosis of COVID-19.
Procedures
During the study period RT-PCR for SARS-CoV-2 was
performed on material obtained from a combined nasal
and throat swab in patients presenting with symptoms
suggestive of COVID-19 who were admitted to hospital.
Repeat testing was at the discretion of the clinician re-
sponsible for care. Although patients were enrolled and
underwent assessment and sampling at three hospitals in
the region, RT-PCR was performed in a single regional
virology laboratory at the Royal Infirmary of Edinburgh.
All specimens were extracted using a single standardised
protocol. Material obtained from the combined nose and
throat swabs were added to a viral transport media
(Remel MicroTest M4RT). Subsequently, an automated
NucliSENS® easyMag® (bioMérieux) platform was used
to obtain 110 μL of eluate containing purified ribo-
nucleic acid (RNA) after 200 μL of the sample was added
to 1 mL of easyMAG lysis buffer. The vast majority of
tests (94%) were performed using a modified in-house
RT-PCR [9] and only a small number of samples (6%)
were analysed using the AllplexTM2019- nCoV Assay
from SeeGene (Seoul, South Korea) [10].
An electronic form was embedded into the order of
the combined nasal and throat swab to prospectively
record information on the indication for testing, symp-
tom type, and duration of symptoms. This form was
completed by the usual care clinician at the time of test-
ing. Data was extracted from the electronic patient rec-
ord (TrakCare; InterSystems Corporation, Cambridge,
MA, USA), laboratory information management system
(iLaboratory, Advanced Expert Systems Medical, Derby,
United Kingdom), the Scottish Morbidity Record, the
Scottish Drug Dispensing Database, and the Scottish
Care Information store. The Scottish Index of Multiple
Deprivation (SIMD), an area-based measure of
deprivation, was used to define socioeconomic status of
each individual based on 31 indicators across 7 domains
(income, employment, health, education, skills and train-
ing, housing, geographic access, and crime) [11].
Outcomes
Diagnostic performance of the index test was evaluated
for a primary outcome of probable or confirmed
COVID-19, and a secondary outcome of confirmed
COVID-19 on serial testing. All clinical diagnoses were
adjudicated by an independent, inter-disciplinary panel
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of clinicians using all information available within the
electronic patient record, including contact history and
review of all laboratory and radiological imaging
performed.
The diagnosis of COVID-19 was based on the case
definition proposed by the World Health Organisation
[12]. The panel identified patients as suspected COVID-
19 where they were admitted to hospital with an acute
respiratory illness (fever with at least one sign or symp-
tom of respiratory disease such as cough or shortness of
breath) and had no alternative diagnosis that fully ex-
plained the clinical presentation. The panel recorded
clinical, laboratory and radiological features of suspected
COVID-19 without knowledge of the index and subse-
quent test results. Patients with parameters consistent
with COVID-19 were subsequently classified as probable
COVID-19 where all tests for the SARS-CoV-2 virus
from any sample type were negative, or confirmed
COVID-19 where any test was positive during the hos-
pital episode, or within 7 days of the index presentation
in those discharged.
For the evaluation of diagnostic performance for the
primary outcome, patients were classified into the fol-
lowing groups: 1) Confirmed COVID-19 in those with
acute respiratory illness AND a positive test for SARS-
CoV-2 (true positives); 2) Probable COVID-19 in those
with acute respiratory illness AND negative tests for
SARS-CoV-2 AND no other diagnosis to explain the
clinical presentation (false negatives); 3) Alternative
diagnosis that fully explained their clinical presentation
AND a positive test for SARS-CoV-2 (false positive); or
4) Alternative diagnosis that fully explained their clinical
presentation AND negative tests for SARS-CoV-2 (true
negatives).
For evaluation of diagnostic performance for the sec-
ondary outcome, patients with confirmed COVID-19
were classified as true positives, and those with probable
COVID-19 were classified as true negatives rather than
false negatives.
Sample size and power
Based on data from the Hubei and Shandong provinces
and Beijing, China, we anticipated that approximately
32% (126/398) of combined nasal and throat swabs per-
formed would be positive for SARS-CoV-2 [6]. We rec-
ognise that there may be differences in the approach to
the selection of patients for testing between countries,
and therefore our sample size was based on a more
Fig. 1 Flow diagram of study population
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conservative positive test rate of 20%. We estimated that
with 1000 patients, we would have 80% power to esti-
mate the confidence interval for a sensitivity of 90% with
lower and upper intervals of 85 and 95% respectively.
Statistical analysis
Baseline characteristics, clinical features, and laboratory
results are summarised as number (percentage) or me-
dian (interquartile range) for the study population, and
stratified according to the adjudicated diagnosis. Quanti-
tative variables were compared in patients with and
without the primary and secondary outcomes using
parametric (Student t test) and non-parametric (Mann-
Whitney U) tests as appropriate, and qualitative variables
were compared using either Chi-squared test or Fisher’s
exact test as appropriate. Statistical significance was set
at P < 0.05. Two-by-two contingency tables were con-
structed to compare the index test (positive or negative)
in those with and without the primary and secondary
outcome on serial testing (reference standard). Test sen-
sitivity, specificity, negative predictive value (NPV) and
positive predictive value (PPV) with 95% confidence in-
tervals was determined in all participants and in pre-
specified subgroups including age, sex, duration of
symptoms prior to testing, fever, and respiratory tract
symptoms. In patients where more than one test was
performed, we report test results and compare diagnos-
tic performance of the index test with the performance
of multiple tests. All analyses were performed using R
(version 3.6.1).
Results
Between April 3 and 20, 2020, we enrolled 1368 con-
secutive patients (median age 68 [interquartile range,
IQR 53–80] years, 47% women) who underwent a total
of 3822 combined nasal and throat swab tests (median 2
[IQR 1–3] tests per patient) for symptoms of suspected
COVID-19 (Fig. 1). The primary outcome occurred in
36% (496/1368), of whom 65% (323/496) and 35% (173/
496) had confirmed and probable COVID-19, respect-
ively. Of those with an alternative diagnosis (64% [872/
1269]), the most frequent diagnoses were other respira-
tory infections (25%, [221/872]) and non-communicable
cardiorespiratory conditions (21%, [181/872]), such as
heart failure, chronic obstructive pulmonary disease and
asthma.
Patients with confirmed or probable COVID-19 were
older than those with an alternative diagnosis (median
age of 71 [57–82] versus 67 [53–80] years), and were less
likely to be from an area of deprivation (13% [65/496]
versus 20% [174/872]). However, they had similar co-
morbidities and were as likely to be receiving angioten-
sin converting enzyme inhibitors, corticosteroids or
immunosuppressants at presentation (Table 1).
Compared to patients with an alternative diagnosis,
those with confirmed or probable COVID-19 had a
lower lymphocyte and neutrophil count (median 1.14 ×
109/L versus 1.44 × 109/L and 5.8 × 109/L versus 6.4 ×
109/L, respectively), but a higher C-reactive protein con-
centration (52 mg/dL versus 22 mg/dL) at presentation
(eTable 1 in the Supplement). In patients with probable
or confirmed COVID-19, compared to those with an al-
ternative diagnosis, some symptoms and signs were
more common, including fever on presentation (65%
[322/496] versus 42% [369/872]), upper and lower re-
spiratory tract symptoms (13% [63/496] versus 9% [78/
872]; 85% [419/496] versus 54% [473/872], respectively),
and systemic symptoms (52% [257/496] versus 28%
[244/872]). In contrast, there were no differences in the
frequency of neurological (24% [118/496] versus 22%
[191/872]) or gastrointestinal symptoms (22% [107/496]
versus 24% [209/872]) (Table 1 and Fig. 2a). Patients
with probable or confirmed COVID-19 were six-times
more likely to have radiological signs of infection on
chest imaging than those with an alternative diagnosis
(64% [316/496] versus 11% [93/872]). Patients with con-
firmed COVID-19 had similar symptoms as those with
probable COVID-19 (Fig. 2b and eTable 2 in the Supple-
ment), but were more likely to have lymphopenia, sys-
temic inflammation and radiological signs of infection
(eTable 3 in the Supplement).
The index test was positive in 255/496 (51%) patients
with the primary outcome (eTable 2 in the Supplement),
giving a sensitivity, specificity, negative predictive value
and positive predictive value of 51.4% (95% confidence
interval [CI] 48.8 to 54.1%), 99.5% (95% CI 99.0 to
99.8%), 78.3% (95% CI 76.0 to 80.4%) and 98.5% (95% CI
97.7 to 99.0%), respectively (Table 2). Sensitivity was
lower in patients from areas with the greatest
deprivation (32.6% [95% CI 21.6 to 43.9%] versus 53.9%
[95% CI 45.7 to 62.1%], quintile with the most
deprivation compared to the quintile with the least
deprivation). Otherwise, sensitivity remained consistent
across other patient demographic factors, comorbidities
and symptoms (Fig. 3a). The negative predictive value of
the index test was consistent across patient demograph-
ics and comorbidities, but was lower in those with fever
(70.3% [95% CI 66.3 to 74.2%]), lower respiratory symp-
toms (69.5% [95% CI 66.1 to 73.0%]) and those with a
longer duration of symptoms prior to hospital admission
(68.7% [95% CI 63.2 to 74.1%] versus 87.1% [95% CI
83.3 to 90.7%] for patients presenting ≥4 days after
symptom onset compared to those presenting within 1
day) (Fig. 3b).
The majority of patients underwent serial testing
(59.6%, 815/1368) with 22.7% (310/1368) undergoing 4
or more serial tests (eFigure 1 and 2, and eTable 4 in the
Supplement). Of those with confirmed COVID-19,
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patients with a negative index test result underwent
more serial testing than those with a positive index test
result (95.6% [65/68] versus 65.9% [168/255] with
median test per patient of 4 [2–6] versus 2 [1–5] re-
spectively). The median time between first and second
tests was shorter in patients with confirmed COVID-19








Age, years 68 (53, 80) 71 (57, 82) 67 (51, 78) < 0.001
Sex 0.078
Men 731 (53%) 281 (57%) 450 (52%)
Women 637 (47%) 215 (43%) 422 (48%)
Ethnicity 0.83
White 1087 (97%) 372 (97%) 715 (98%)
Other 29 (2.6%) 11 (2.9%) 18 (2.5%)
Deprivationb 0.002
1 (most deprivation) 239 (18%) 65 (13%) 174 (20%)
2 321 (24%) 116 (24%) 205 (24%)
3 236 (17%) 79 (16%) 157 (18%)
4 243 (18%) 93 (19%) 150 (17%)
5 (least deprivation) 319 (23%) 139 (28%) 180 (21%)
Duration of symptoms, days 3.0 [1.0–5.0] 3.0 [2.0–7.0] 2.0 [1.0–4.0] < 0.001
Clinical features
Fever 691 (51%) 322 (65%) 369 (42%) < 0.001
Upper respiratory tract symptoms 141 (10%) 63 (13%) 78 (9%) 0.034
Lower respiratory tract symptoms 891 (65%) 419 (85%) 472 (54%) < 0.001
Systemic symptoms 501 (37%) 257 (52%) 244 (28%) < 0.001
Neurological symptoms 309 (23%) 118 (24%) 191 (22%) 0.45
Gastrointestinal symptoms 316 (23%) 107 (22%) 209 (24%) 0.36
Lymphopenia 894 (65%) 406 (82%) 488 (56%) < 0.001
Inflammation 986 (72%) 421 (86%) 565 (65%) < 0.001
Radiological signs 409 (30%) 316 (64%) 93 (11%) < 0.001
Comorbidities
Diabetes mellitus 251 (18%) 96 (19%) 155 (18%) 0.51
Ischemic heart disease 136 (10%) 45 (9.1%) 91 (11%) 0.44
Heart failure 112 (8.3%) 38 (7.7%) 74 (8.6%) 0.62
Stroke 82 (6.0%) 27 (5.4%) 55 (6.3%) 0.60
COPD 206 (15%) 58 (12%) 148 (17%) 0.011
Asthma 113 (8.3%) 30 (6.0%) 83 (9.5%) 0.033
Liver cirrhosis 27 (2.0%) 8 (1.6%) 19 (2.2%) 0.60
End stage kidney disease 25 (1.8%) 12 (2.4%) 13 (1.5%) 0.31
Medications at presentation
ACE inhibitors or ARBs 336 (25%) 129 (26%) 207 (24%) 0.38
Corticosteroids 223 (16%) 73 (15%) 150 (17%) 0.27
Immunosuppressants 34 (2.5%) 15 (3.0%) 19 (2.2%) 0.43
Values are No. (%) or median [inter-quartile range]
Abbreviations: ACE angiotensin converting enzyme, ARB angiotensin receptor blockers, COPD chronic obstructive pulmonary disease
aConfirmed or probable COVID-19 with no alternative diagnosis
bScottish Index of Multiple Deprivation (SIMD) quintiles
‡Comparison between patients with COVID-19 versus those with alternative diagnosis
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who had a negative index test result and those with
probable COVID-19 (1.7 [0.8–10.9] days and 1.2 [0.9–
4.6] days respectively) compared to patients with con-
firmed COVID-19 who had a positive index test result
and those with an alternative diagnosis (6.8 [4.0–8.6]
days and 6.1 [1.1–21.8] days respectively). Sensitivity for
the primary outcome increased in those undergoing 2, 3
or 4 serial tests to 60.1% (95% CI 56.7 to 63.4%), 68.3%
(95% CI 64.0 to 72.3%) and 77.6% (95% CI 72.7 to
81.9%), respectively (Table 2 and Fig. 4). The negative
predictive value increased more modestly on serial
testing; from 78.3% (76.0 to 80.4%) for the index test to
79.8% (75.0 to 83.9%) in those undergoing 4 serial tests.
These observations persisted in a sensitivity analysis re-
stricted to patients who underwent at least 4 tests and
for the secondary outcome (Fig. 4, eFigure 3 and 4, and
eTable 5 in the Supplement).
Sensitivity of the index test for the secondary outcome
of a diagnosis of confirmed COVID-19 on serial testing
was 78.9% (95% CI 74.4 to 83.2%) (eFigure 5a in the
Supplement). There was no significant heterogeneity in
sensitivity across patient demographics, comorbidities or
Fig. 2 Radar plot of the clinical features of patients with (a) an adjudicated diagnosis of confirmed or probable COVID-19 and those with an
alternative diagnosis, and (b) confirmed COVID-19 and those with probable COVID-19. The following features used to adjudicate the diagnosis are
illustrated: fever, systemic symptoms (e.g. myalgia, fatigue, and arthralgia), upper respiratory tract symptoms, lower respiratory tract symptoms,
gastrointestinal symptoms, neurological symptoms, lymphopenia, systemic inflammation, radiological features of infection
Table 2 Diagnostic performance of the index and serial combined nasal and throat swab for the primary outcome of a diagnosis of























868 241 255 4 51.4 (48.8–
54.1)
78.3 (76.0–80.4) 98.5 (97.7–99) 99.5 (99.0–
99.8)
2 459 141 212 5 60.1 (56.7–
63.4)
76.5 (73.5–79.3) 97.7 (96.4–98.5) 98.9 (98.0–
99.4)
3 235 76 164 7 68.3 (64.0–
72.3)
75.6 (71.5–79.2) 95.9 (93.7–97.3) 97.1 (95.2–
98.3)
4 142 36 125 7 77.6 (72.7–
81.9)
79.8 (75.0–83.9) 94.7 (91.6–96.7) 95.3 (92.3–
97.2)
5 94 24 94 6 79.7 (73.8–
84.5)
79.7 (73.8–84.5) 94.0 (90.0–96.5) 94.0 (90.0–
96.5)
6 62 11 75 6 87.2 (81.0–
91.6)
84.9 (78.4–89.7) 92.6 (87.3–95.8) 91.2 (85.6–
94.7)
7 46 10 55 6 84.6 (77.0–
90.0)
82.1 (74.2–88.0) 90.2 (83.4–94.3) 88.5 (81.4–
93.1)
8 31 6 43 4 87.8 (79.1–
93.2)
83.8 (74.5–90.2) 91.5 (83.6–95.8) 88.6 (80.0–
93.7)
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presenting symptoms. The negative predictive value of
the index test was 93.8% (95% CI 92.4 to 95.2%) for a
diagnosis of confirmed COVID-19 on serial testing (eFi-
gure 5b in the Supplement). The negative predictive
value remained consistent across patient demographics
and comorbidities, but was lower in patients who pre-
sented with a fever (89.6% [95% CI 86.9 to 92.1%]) and
those who had lower respiratory symptoms (91.5% [95%
CI 89.4 to 93.6%]).
Discussion
In this prospective, multi-centre, cohort study, we evalu-
ated the diagnostic performance of the combined nasal
and throat swab with RT-PCR for SARS-CoV-2 in con-
secutive patients admitted to hospital with symptoms of
suspected COVID-19. We report a number of potentially
important findings. First, a single test had excellent spe-
cificity, but limited sensitivity for an adjudicated diagno-
sis of probable or confirmed COVID-19. Second, the
Fig. 3 Forest plot of the (a) sensitivity and (b) negative predictive value of the index combined nasal and throat swab for a diagnosis of
confirmed or probable COVID-19 stratified by subgroups
Fig. 4 Sensitivity of serial testing using the combined nasal and throat swab for the primary (confirmed or probable COVID-19) and secondary
(confirmed COVID-19) outcome
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sensitivity of the index test was higher for patients with
confirmed COVID-19 on serial testing, but still missed 1
in 5 patients with the diagnosis. Third, diagnostic per-
formance was similar in most patient subgroups, but the
sensitivity was lower in those from more deprived areas,
and the negative predictive value was lower in those pre-
senting later following the onset of symptoms, and in
those with fever or lower respiratory symptoms. Finally,
we observed a significant improvement in diagnostic
sensitivity with repeated testing on up to four occasions.
Our study has several strengths. This was a prospect-
ive, multi-centre study that was adequately powered to
evaluate the diagnostic performance of the combined
nasal and throat swab. Patients were enrolled using an
electronic form embedded within clinical care across all
secondary and tertiary hospitals in the region. This per-
mitted us to include all consecutive patients who under-
went testing for symptoms that were considered to be
suggestive of COVID-19 by their usual care clinician
minimizing selection bias and ensuring our findings are
representative of all hospitalised patients across the re-
gion. The diagnosis was adjudicated by a multidisciplin-
ary panel of clinicians from a range of specialities
involved in the care of patients with COVID-19, includ-
ing infectious disease, emergency medicine, general
medicine and geriatric medicine, and therefore our find-
ings are relevant to clinical practice across secondary
and tertiary care settings.
To our knowledge this is the first evaluation of the
diagnostic performance of the combined nasal and
throat swab for a clinical diagnosis of COVID-19. The
evaluation of the combined nasal and throat swab is par-
ticularly important since this is the most widely used
diagnostic modality to identify or exclude SARS-CoV-2
infection. Although the RT-PCR test for SARS-CoV-2
has excellent in vitro analytical performance under care-
fully controlled laboratory conditions [9], diagnostic per-
formance in clinical practice can vary due to multiple
other factors, such as the site and quality of sampling,
stage of disease, and viral multiplication or clearance [3,
6, 13]. Previous studies have reported diagnostic sensitiv-
ities ranging from 50 to 100% for the combined nasal
and throat swab with a meta-analysis reporting a pooled
meta-estimate of 89% (95% CI 81 to 94%) [4, 6, 14–17].
However, these studies have been performed in relatively
small, selected patient cohorts, which limit the generalis-
ability of study findings across the breadth of patients
presenting to hospitals with suspected COVID-19. Fur-
thermore, the reference standard used in these studies
was either radiological findings on chest computed tom-
ography, or the results of subsequent RT-PCR tests,
which inevitably leads to an increase in the estimated
diagnostic sensitivity. Indeed, when our reference stand-
ard was restricted to confirmed COVID-19 on serial
testing, diagnostic sensitivity increased from 51.4 to
78.9%.
In subgroup analyses, the diagnostic performance was
similar in older patients, those with diabetes, known re-
spiratory or cardiovascular disease. These findings are
reassuring since these patient subgroups have been iden-
tified as those at the highest risk of death from COVID-
19 [18–20]. However, we observed that diagnostic sensi-
tivity was lower in patients from the most deprived
areas. This may reflect differences in the clinicians ap-
proach to testing by deprivation, rather than a conse-
quence of deprivation itself, but this requires further
evaluation. Furthermore, we observed that negative pre-
dictive value was lower in those who presented late in
the course of their illness, and those with symptoms of
fever and lower respiratory tract symptoms. This is con-
sistent with virological assessments of patients hospita-
lised with COVID-19 which showed that viral RNA
shedding from the upper respiratory tract is typically
highest at the onset of symptoms, but subsequently de-
clines as the disease progresses [13, 21]. The lower nega-
tive predictive value in those with typical clinical
symptoms is likely to reflect a higher pre-test probability
for COVID-19 in these patients.
Our findings have potentially important implications
for the use and interpretation of this test in clinical prac-
tice. Whilst the diagnosis of COVID-19 is still largely re-
liant on RT-PCR on material collected on nose and
throat swabs, clinicians need to be aware of the strengths
and limitations of testing when making decisions on the
placement of patients within hospital settings and dis-
charge planning. In our study, the most conservative es-
timate of diagnostic sensitivity was 51%, where the index
test was negative in 1 in 2 patients with the primary out-
come of probable or confirmed COVID-19. Our most
optimistic estimate of diagnostic sensitivity was 79%,
where the index test was negative in 1 in 5 patients with
the secondary outcome of confirmed COVID-19. Whilst,
the former may underestimate performance, the latter is
certainly an overestimate due to circular reasoning,
whereby the test under evaluation is an essential compo-
nent of the reference standard.
In this consecutive series of hospitalised patients
where testing was performed for symptoms at the dis-
cretion of the usual care clinician, our multi-disciplinary
panel diagnosed probable COVID-19 in 12.6% of pa-
tients. The panel included representation from a broad
range of medical specialities involved in the assessment
of these patients, and therefore their judgment is likely
to be representative of clinical practice. Our approach
aims to provide insights into the performance of the test
as it is applied in clinical practice. Interestingly patients
with probable COVID-19 or confirmed COVID-19 and
a negative index test were more likely to be retested
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within the next 24–48 h. This likely reflects the usual care
clinician’s uncertainty when interpreting a negative test. In-
deed for both the primary and secondary outcome, diagnos-
tic performance improved significantly with up to four serial
tests, and this observation could inform our approach to ser-
ial testing in practice with implications for patient flow and
management of hospitalised patients. Our findings also have
implications when defining the reference standard for stud-
ies evaluating the performance of point of care [22] and la-
boratory antibody tests [23] to determine those with and
without prior infection. Future research should evaluate per-
formance in patients undergoing testing in the community,
and determine whether performance can be improved by in-
corporating a measure of sampling efficacy using epithelial
cell counts [24], or whether the diagnostic yield is higher in
other sample types, such as saliva or sputum.
We acknowledge our study has several limitations. We
did not mandate the number of serial tests as all diag-
nostic testing was performed at the discretion of the
treating clinician. Therefore those with a negative index
test undergoing serial testing are likely to have had a
higher pre-test probability than those undergoing a sin-
gle test. Conversely, patients with a positive index test
may have received testing due to uncertainty in the clin-
ical diagnosis. Furthermore, during the conduct of this
study, our institutional protocol recommended repeat
testing when patients are transferred to different clinical
areas; for example from a high dependency unit to a
general ward. Nevertheless, it is reassuring that a similar
increase in diagnostic performance with serial testing
was observed in a sensitivity analysis restricted to those
patients who had a complete series of at least four tests.
Further studies with systematic sampling in consecutive
patients are required to validate this observation. In the
absence of an independent gold standard test for the
diagnosis of COVID-19, our diagnostic evaluation was
based on clinical review of all tests ordered by the usual
care clinician. As a comprehensive panel of respiratory
pathogens was not requested in all patients, it is likely
we have misclassified some patients as COVID-19 who
had other viral or bacterial infections. We may have
overestimated the diagnosis of COVID-19 given the
study was performed during the peak of a pandemic.
However, we reviewed all available clinical investigations
including all laboratory and imaging findings, and only
defined patients with suspected COVID-19 where there
was no alternative diagnosis. Furthermore, the clinical
features of those with probable or confirmed COVID-19
were identical, suggesting no systematic bias was intro-
duced during the adjudication.
Conclusions
In conclusion, a single combined nasal and throat swab
with RT-PCR for SARS-CoV-2 has excellent specificity,
but limited diagnostic sensitivity for the clinical diagno-
sis of COVID-19. Diagnostic performance is significantly
improved by repeated testing.
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